Cell and Gene Therapy CDMO Market Size, Trends, Analysis, and Outlook By Phase (Pre-clinical, Clinical, By Product (Gene Therapy (Ex-vivo, In-vivo, Gene-Modified Cell Therapy, CAR T-cell therapies, CAR-NK cell therapy, TCR-T cell therapy, Others), Cell Th

Cell and Gene Therapy CDMO Market Size, Trends, Analysis, and Outlook By Phase (Pre-clinical, Clinical, By Product (Gene Therapy (Ex-vivo, In-vivo, Gene-Modified Cell Therapy, CAR T-cell therapies, CAR-NK cell therapy, TCR-T cell therapy, Others), Cell Therapy), By Indication (Oncology, Infectious Diseases, Neurological disorders, Rare Diseases, Others), by Region, Country, Segment, and Companies, 2024-2030

The global Cell and Gene Therapy CDMO market size is poised to register 23.52% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Cell and Gene Therapy CDMO market across By Phase (Pre-clinical, Clinical, By Product (Gene Therapy (Ex-vivo, In-vivo, Gene-Modified Cell Therapy, CAR T-cell therapies, CAR-NK cell therapy, TCR-T cell therapy, Others), Cell Therapy), By Indication (Oncology, Infectious Diseases, Neurological disorders, Rare Diseases, Others).

The cell and gene therapy contract development and manufacturing organization (CDMO) market is experiencing rapid growth, influenced by various factors in 2024 and beyond. With the increasing interest and investment in cell and gene therapies for the treatment of various genetic and chronic diseases, there is a growing demand for specialized manufacturing services to support the development and commercialization of these advanced therapeutics. Market growth is driven by the expanding pipeline of cell and gene therapy candidates, the complexity of manufacturing processes, and the need for scalable and cost-effective production solutions. Moreover, the outsourcing of manufacturing activities to CDMOs allows biopharmaceutical companies to access specialized expertise, infrastructure, and technologies, enabling them to accelerate product development and reduce time to market. Additionally, the growing regulatory support for advanced therapy medicinal products (ATMPs) and the increasing adoption of personalized medicine approaches are propelling market expansion. Furthermore, strategic collaborations between CDMOs, biopharmaceutical companies, and academic institutions are driving innovation and shaping industry dynamics, fostering the development of novel manufacturing platforms and process optimization strategies.

Cell and Gene Therapy CDMO Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Cell and Gene Therapy CDMO market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Cell and Gene Therapy CDMO survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Cell and Gene Therapy CDMO industry.

Key market trends defining the global Cell and Gene Therapy CDMO demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Cell and Gene Therapy CDMO Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Cell and Gene Therapy CDMO industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Cell and Gene Therapy CDMO companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Cell and Gene Therapy CDMO industry

Leading Cell and Gene Therapy CDMO companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Cell and Gene Therapy CDMO companies.

Cell and Gene Therapy CDMO Market Study- Strategic Analysis Review

The Cell and Gene Therapy CDMO market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Cell and Gene Therapy CDMO Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Cell and Gene Therapy CDMO industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Cell and Gene Therapy CDMO Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Cell and Gene Therapy CDMO Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Cell and Gene Therapy CDMO market segments. Similarly, Strong end-user demand is encouraging Canadian Cell and Gene Therapy CDMO companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Cell and Gene Therapy CDMO market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Cell and Gene Therapy CDMO Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Cell and Gene Therapy CDMO industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Cell and Gene Therapy CDMO market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Cell and Gene Therapy CDMO Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Cell and Gene Therapy CDMO in Asia Pacific. In particular, China, India, and South East Asian Cell and Gene Therapy CDMO markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Cell and Gene Therapy CDMO Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Cell and Gene Therapy CDMO Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Cell and Gene Therapy CDMO market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Cell and Gene Therapy CDMO.

Cell and Gene Therapy CDMO Market Company Profiles

The global Cell and Gene Therapy CDMO market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Lonza, CatalentInc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc, Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories

Recent Cell and Gene Therapy CDMO Market Developments

The global Cell and Gene Therapy CDMO market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Cell and Gene Therapy CDMO Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Phase

Pre-clinical

Clinical

By Product

Gene Therapy

Ex-vivo

In-vivo

Gene-Modified Cell Therapy

CAR T-cell therapies

CAR-NK cell therapy

TCR-T cell therapy

Others

Cell Therapy

By Indication

Oncology

Infectious Diseases

Neurological disorders

Rare Diseases

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

Lonza

CatalentInc

Cytiva

Samsung Biologics

Thermo Fisher Scientific Inc

Novartis AG

WuXi AppTec

AGC Biologics

OmniaBio

Rentschler Biopharma SE

Charles River Laboratories

Formats Available: Excel, PDF, and PPT